EcoDrugPlus

Proteasome 20s Subunit Alpha 2b

Ensembl ID : ENSSFOG00015026284
Gene Symbol: PSMA2B
1 Cross references
266 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSSFOG00015019194
Gene Symbol: PSMA3
3 Cross references
240 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSSFOG00015010581
Gene Symbol: PSMA4
3 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSSFOG00015020508
Gene Symbol: PSMA5
3 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 6a

Ensembl ID : ENSSFOG00015004208
Gene Symbol: PSMA6A
1 Cross references
323 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSSFOG00015010234
Gene Symbol: PSMA8
3 Cross references
197 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSSFOG00015015260
Gene Symbol: PSMB1
1 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSSFOG00015022111
Gene Symbol: PSMB2
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSSFOG00015003420
Gene Symbol: PSMB3
3 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSSFOG00015005028
Gene Symbol: PSMB4
1 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSSFOG00015017508
Gene Symbol: PSMB6
3 Cross references
242 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSSFOG00015015709
Gene Symbol: PSMB8
3 Cross references
220 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).